KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1054-1065

  Hassig, Christian A ^a   Symons, Kent T ^a   Guo, Xin ^a   Nguyen, Phan Manh ^a   Annable, Tami ^a   Wash, Paul L ^a   Payne, Joseph E ^a   Jenkins, David A ^a   Bonnefous, Céline ^a   Trotter, Carol ^a   Wang, Yan ^a   Anzola, John V ^a   Milkova, Elena L ^a   Hoffman, Timothy Z ^a   Dozier, Sara J ^a   Wiley, Brandon M ^a   Saven, Alan ^b   Malecha, James W ^a   Davis, Robert L ^a   Muhammad, Jerry ^a   Shiau, Andrew K ^a   Noble, Stewart A ^a   Rao, Tadimeti S ^a   Smith, Nicholas D ^a   Hager, Jeffrey H ^a   more..

^a Kalypsys Inc   (United States)

^b SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KD 5170; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PYRIDINE DERIVATIVE; SULFONAMIDE;

ACETYLATION; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG SCREENING; IC 50; MALE; NUDE MOUSE; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSTATIC NEOPLASMS; PYRIDINES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49849106385     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2347     Document Type: Article

References (47)

1. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
2. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer. Part I. Covalent histone modifications. Trends Mol Med 2007;13:363-72.
3. Gallinari P, Di MS, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007;17:195-211.
4. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52.
5. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005;363:15-23.
6. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000;19:1176-9.
7. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007;74:659-71.
8. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6.
9. Suzuki T, Miyata N. Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 2005;12:2867-80.
10. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small molecule HDAC inhibitors. Biochem J 2008;409:581-9.
11. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
12. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36.
13. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
14. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38.
15. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9.
16. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
17. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
18. Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007;21:61-5.
19. Hassig CA, Tong JK, Fleischer TC, et al. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A 1998;95:3519-24.
20. Matsuyama A, Shimazu T, Sumida Y, et al. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 2002;21:6820-31.
21. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
22. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241:142-50.
23. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
24. Remiszewski SW. The discovery of NVP-LAQ824: from concept to clinic. Curr Med Chem 2003;10:2393-402.
25. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
26. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess yc changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997;411:77-82.
27. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62.
28. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 2006;24:152-60.
29. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999;291:739-48.
30. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-9.
31. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
32. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006;12:634-42.
33. Baylin SB, Chen WY. Aberrant gene silencing in tumor progression: implications for control of cancer. Cold Spring Harb Symp Quant Biol 2005;70:427-33.
34. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profilingof multiple histone deacetylase (HDAC) inhibitors: defininga common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63.
35. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5.
36. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-702.
37. Rubin B, Antonaccio MJ, Horovitz ZP. Captopril (SQ 14,225) (D-3-mercapto-2-methylpropranoyl-L-proline): a novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent. Prog Cardiovasc Dis 1978;21:183-94.
38. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480-5.
39. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32.
40. Suzuki T, Kouketsu A, Matsuura A, et al. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem Lett 2004;14:3313-7.
41. Vanommeslaeghe K, Loverix S, Geerlings P, Tourwe D. DFT-based ranking of zinc-bindingg roups in histone deacetylase inhibitors. Bioorg Med Chem 2005;13:6070-82.
42. Nakagawa M, Oda Y, Eguchi T, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007;18:769-74.
43. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005;4:549-51.
44. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007;6:1483-91.
45. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
46. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67.
47. Karagiannis TC, El-Osta A. Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 2006;1:121-6.